PBM
CORT icon

Propel Bio Management’s Corcept Therapeutics CORT Stock Holding History

Propel Bio Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Sell
136,499
-11,329
-8% -$684K 6.21% 3
2026
Q1 		$6.02M Buy
+147,828
New +$5.53M 3.8% 5

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Propel Bio Management's CORT Position: Q2 2026 in Review

Propel Bio Management reduced its Corcept Therapeutics (CORT) stake by 7.7% in Q2 2026, selling an estimated $684K and leaving 136,499 shares worth $11.9M. The position accounts for 6.21% of the portfolio, ranked #3.

Propel Bio Management first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Propel Bio Management held 136,499 shares of Corcept Therapeutics worth $11.9M as of Q2 2026.
  • Propel Bio Management sold 11,329 Corcept Therapeutics shares in Q2 2026, an estimated $684K.
  • Corcept Therapeutics made up 6.21% of Propel Bio Management's portfolio in Q2 2026, its #3 holding.
  • Propel Bio Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.